# To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

Source: https://onco.cc/trials/nct06378242/  
OnCo record `nct06378242` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Disitamab vedotin in bladder & urothelial cancer, run by RemeGen Co., Ltd., now recruiting.

## Summary

To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2 is a phase 1/2 interventional study registered as NCT06378242 by RemeGen Co., Ltd., with 24 participants planned, started 2024-06-14 and due to reach its primary completion in 2029-03-15. Interventions recorded: Disitamab Vedotin for injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06378242
- Phase: 1/2
- Setting: An Single-arm, Multicenter Phase I/II Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
- Sponsor: RemeGen Co., Ltd.
- Enrolled: 24

## Sources

- ClinicalTrials.gov NCT06378242: https://clinicaltrials.gov/study/NCT06378242

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Disitamab vedotin](https://onco.cc/drugs/disitamab-vedotin/)
- companies: [RemeGen](https://onco.cc/companies/remegen/)

---
JSON: https://onco.cc/api/v1/entities/nct06378242.json